Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Pulmonary Medicine|July 21, 2022
Management of fibrotic hypersensitivity pneumonitisMonica L Mullin, Andrew Churg, Christopher J Ryerson
BMJ Case Reports|February 14, 2025
Successful multimodal endobronchial treatment of severe tracheobronchial amyloidosisMonica L Mullin, Roisin Dunwoody, Neal Navani, et al.
JTO Clinical and Research Reports|June 8, 2026
Brief Report: Impact of PLCOm2012 Ethnicity Model Variations on Eligibility for the Alberta Lung Cancer Screening ProgramMatthew T Warkentin, Kirk Graff, Darren R Brenner, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Characterizing Regional Variability in Lung Cancer Outcomes across Ontario-A Population-Based AnalysisMonica L Mullin, Jonas Shellenberger, Marlo Whitehead, et al.
Breathe (Sheffield, England)|August 28, 2024
Lung cancer screening: where do we stand?Georgia Hardavella, Armin Frille, Katherina Bernadette Sreter, et al.
Chest|December 21, 2023
Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity PneumonitisMonica L Mullin, Gustavo Fernandez, Daniel-Costin Marinescu, et al.
Thorax|February 2, 2026
Upstaging of screen-detected lung cancers during diagnostic assessmentMonica L Mullin, Priyam Verghese, Chuen R Khaw, et al.
Chest|June 30, 2026
Symptom prevalence and impact on lung cancer risk in the SUMMIT studyMonica L Mullin, Andrew W Creamer, Amyn Bhamani, et al.
Cytotherapy|April 3, 2026
A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancerRebecca N Graham, Alice Davies, Monica L Mullin, et al.
BMJ Open Respiratory Research|September 11, 2025
Differentiating clinically important interstitial lung abnormalities in lung cancer screeningBrintha Selvarajah, Amyn Bhamani, Mehran Azimbagirad, et al.
Pageof 1